Novartis Inc
NOVN
ISIN CH0012005267 / Valor 1200526
Novartis Inc
UMushroom community rating:
About company
Novartis Inc. is a global healthcare company that specializes in the development and distribution of innovative medicines. With a focus on addressing unmet medical needs, Novartis aims to improve and extend the lives of people suffering from serious diseases. The company operates in several core therapeutic areas, including cardiovascular, renal and metabolic diseases, immunology, neuroscience, and oncology. Novartis is known for its commitment to research and development, leveraging advanced technology platforms to create groundbreaking therapies. With a workforce of approximately 78,000 employees representing over 140 nationalities, Novartis has a significant global presence, reaching more than 284 million patients worldwide. The company's strategy revolves around delivering high-value medicines and employing novel access approaches to alleviate some of society's most significant disease burdens.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (20.10.2025):
Novartis Inc reported strong financial performance in the second quarter of 2025, demonstrating significant growth in key areas compared to the same period in the previous year. The company achieved increased net sales, operating income, net income, earnings per share, and free cash flow, reflecting its robust operational efficiency and strategic initiatives.
Net Sales Growth
Net sales for Q2 2025 reached USD 14,054 million, marking a 12% increase from USD 12,512 million in Q2 2024. On a constant currency basis, the growth was 11%.
Operating Income
Operating income surged to USD 4,864 million in Q2 2025, up by 21% compared to USD 4,014 million in the same quarter last year. When adjusted for constant currencies, the increase was 25%.
Net Income
Net income for Q2 2025 rose to USD 4,024 million, representing a 24% growth from USD 3,246 million in Q2 2024. On a constant currency basis, the growth was 26%.
Earnings Per Share (EPS)
Earnings per share improved to USD 2.07 in Q2 2025, up by 29% from USD 1.60 in the second quarter of 2024. The constant currency EPS growth stood at 32%.
Free Cash Flow
Free cash flow experienced a substantial increase, reaching USD 6,333 million in Q2 2025 compared to USD 4,615 million in Q2 2024, reflecting a 37% rise.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
254241 M
Market cap (USD)
2,187,946
Daily traded volume (Shares)
88.82 / 87.81
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Karel Bourban
Karel Bourban
Arthur Vallery
EQUITIES OF THE SAME SECTOR
